Ketanest S (Esketamine Hydrochloride)

• Esketamine hydrochloride, an NMDA receptor antagonist, is employed in anesthesia and sedation pathways.
• Induction of general anesthesia: produces rapid unconsciousness and amnesia for surgical procedures.
• Procedural sedation: provides safe, controllable sedation for diagnostic or minor surgical interventions.
• Analgesia: delivers effective pain relief during and after operative procedures.

• Esketamine hydrochloride acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor, binding within the ion channel and preventing calcium influx. This blockade disrupts excitatory neurotransmission, leading to dissociative anesthesia and analgesia. The drug also modulates opioid receptors and influences monoaminergic pathways, contributing to its analgesic and sedative properties without significant respiratory depression. Additionally, it reduces central sensitization to painful stimuli.

Esketamine may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Hypertension: transient increase in blood pressure.
• Tachycardia: elevated heart rate.
• Nausea: feeling of sickness.
• Vomiting: expulsion of stomach contents.
• Dissociation: sense of detachment from environment.
• Psychomimetic symptoms: vivid dreams or hallucinations.

Serious or Rare Side Effects

• Respiratory depression: reduced breathing effort.
• Seizures: convulsive episodes.
• Severe hypertension: sustained high blood pressure.
• Allergic reactions: rash, itching, anaphylaxis.

• When using Ketanest S, clinicians should observe several safety measures to minimize risk.
• Patient assessment: evaluate cardiovascular status and airway before administration.
• Monitoring: continuously observe blood pressure, heart rate, and oxygen saturation during the procedure.
• Drug interactions: avoid concurrent use with other central nervous system depressants unless closely supervised.
• Contraindications: do not use in patients with known hypersensitivity to esketamine or other NMDA antagonists.
• Pregnancy and lactation: consider potential risks as safety data are limited; use only if benefits outweigh risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Esketamine can interact with other medications, affecting its safety profile or efficacy.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.
• CYP2B6 inhibitors (e.g., clopidogrel): may increase esketamine plasma levels.
• Other NMDA antagonists: additive dissociative effects.

Moderate Interactions (Monitor Closely)

• CNS depressants (benzodiazepines, opioids): may enhance sedation and respiratory depression.
• Sympathomimetic agents (e.g., epinephrine): may exacerbate hypertension.
• Serotonergic drugs (SSRIs, SNRIs): monitor for serotonin syndrome signs.